The study is designed to investigate the effectiveness of using platelets and growth factors taken from the patient’s blood, called autologous conditioned plasma (ACP), and then injected into the affected area. Possible benefits of ACP may include significant decrease in knee pain and improved knee function and range of motion.
ACP (autologous conditioned plasma) is a substance with remarkable healing properties derived from blood and used to treat injuries and arthritis. ACP contains a concentrate of growth factors and platelets which signal a reparative process when injected into damaged tissue.
A small quantity of blood is required for the procedure which is drawn into a specialized double syringe system and then spun in a centrifuge machine until plasma rich in platelets and growth factors is isolated. This plasma is then drawn out and injected into the affected joint to promote healing.
The entire procedure takes about 30 minutes to perform. You may receive three treatments a week apart. ACP is a new treatment currently being researched. Your doctor will explain the procedure and the risks involved before obtaining your consent.
You are eligible if you:
- Are between the ages of 18 and 70
- Have had continued knee pain for the past 6 weeks
- Have been diagnosed with osteoarthritis (grade II or III)
Those interested in the clinical trial should call: 312-912-4701 or
The orthopedic specialists at Midwest Orthopaedics at Rush are involved in numerous clinical studies to test the effectiveness and safety of new therapies and treatment, as well as to expand scientific and medical knowledge. If you are interested in one of our clinical studies, please use the contact information provided for the individual trial to get more information.